The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy ...The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy and IL4-signaling targeting strategies as a promising new approach for the treatment of advanced OvCa.Ovarian Cancer(OvCa)is the third most common gynecological malignant disease affecting women.2 It is often diagnosed at late stages and is characterized by heterogenous features with limited treatment options.Initial response to standard of care platinumbased chemotherapy combined with surgery is often followed by disease relapse and subsequent death of patients.Despite the recent success of immune checkpoint inhibition in different cancer entities,most OvCa patients do not benefit from immunotherapy-based treatment approaches.The responsiveness of ovarian tumors to immune checkpoint blockade(ICB)is thereby hindered by weak immunogenicity due to low mutational burden and an immune suppressive tumor microenvironment(TME)characterized by heterogenous immune cell infiltration.3 Still,functional evidence for key factors that govern cancer cellimmune cell interaction and drive immunotherapy resistance in OvCa remains limited.展开更多
基金funded by the Deutsche Forschungsgemeinschaft(DFG,German Research Foundation,LE 3613/3-1).
文摘The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy and IL4-signaling targeting strategies as a promising new approach for the treatment of advanced OvCa.Ovarian Cancer(OvCa)is the third most common gynecological malignant disease affecting women.2 It is often diagnosed at late stages and is characterized by heterogenous features with limited treatment options.Initial response to standard of care platinumbased chemotherapy combined with surgery is often followed by disease relapse and subsequent death of patients.Despite the recent success of immune checkpoint inhibition in different cancer entities,most OvCa patients do not benefit from immunotherapy-based treatment approaches.The responsiveness of ovarian tumors to immune checkpoint blockade(ICB)is thereby hindered by weak immunogenicity due to low mutational burden and an immune suppressive tumor microenvironment(TME)characterized by heterogenous immune cell infiltration.3 Still,functional evidence for key factors that govern cancer cellimmune cell interaction and drive immunotherapy resistance in OvCa remains limited.
